Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Big Pharma's Investment in Biologics

Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.
May 3, 2013

Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.

Pharma Industry Participates in Vaccine Initiatives

The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.
May 3, 2013

The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.

Academic and Public Partnerships in Solid-State Chemistry

Solid-state chemistry is an important part of drug development, and public research is advancing the field.
May 2, 2013

Solid-state chemistry is an important part of drug development, and public research is advancing the field.

Using Thermal Ink-Jet Printing Technology to Produce Pharmaceutical Cocrystals

Cocrystals are used to improve the performance of APIs that have non-ideal physiochemical properties.
May 2, 2013

Cocrystals are used to improve the performance of APIs that have non-ideal physiochemical properties by cocrystallizing the API with a second compound that modulates the API to provide a way to improve a drug's bioavailability, stability, and processability.

Intellectual Property Battles in Solid-State Chemistry

The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.
May 2, 2013

The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.

Delivering Complex Drugs With Nanotechnology-Based Solutions

Parenteral drug delivery offers a variety of challenges but also opportunities.
May 1, 2013

Parenteral drug delivery offers a variety of challenges but also opportunities. The author examines recent developments in nanotechnology-based drug delivery and other advances in injection-based drug delivery.

Big Pharma's Manufacturing Investments in Biologics

Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing.
May 1, 2013

Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing. The author provides an update in recent investment activity among the pharmaceutical majors in biologic-drug substance, vaccine, and parenteral drug manufacturing.

Bristol-Myers Squibb Plans Expansion of Massachusetts Biologics Facility

The company expands to add process-development and clinical-manufacturing capabilities at its large-scale bulk biologics facility.
Apr 12, 2013

The company expands to add process-development and clinical-manufacturing capabilities at its large-scale bulk biologics facility.

State Legislatures Become Battlegrounds for Biosimilars

Maryland is the latest state to consider whether to include additional requirements for substitution of biological products.
Apr 11, 2013

Maryland is the latest state to consider whether to include additional requirements for substitution of biological products

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here